硝苯地平对普萘洛尔、美托洛尔和阿替洛尔药代动力学及药效学影响的研究。
Study of the influence of nifedipine on the pharmacokinetics and pharmacodynamics of propranolol, metoprolol and atenolol.
作者信息
Gangji D, Juvent M, Niset G, Wathieu M, Degreve M, Bellens R, Poortmans J, Degre S, Fitzsimons T J, Herchuelz A
出版信息
Br J Clin Pharmacol. 1984;17 Suppl 1(Suppl 1):29S-35S. doi: 10.1111/j.1365-2125.1984.tb02425.x.
Abstract
The influence of chronic therapy with nifedipine on the pharmacokinetics of propranolol 80 mg twice daily, metoprolol 100 mg twice daily and atenolol 100 mg once daily was investigated in eight healthy volunteers. Nifedipine 10 mg three times daily did not affect the pharmacokinetics of metoprolol and atenolol whereas nifedipine shortened the time to peak plasma concentration for propranolol by about 1 h. Propranolol, metoprolol and atenolol provoked comparable decreases in heart rate measured at rest and during exercise. The beta-adrenoceptor blocking properties of propranolol, metoprolol and atenolol were not affected by concomitant therapy with nifedipine. The present study did not show significant pharmacokinetic and pharmacodynamic interactions between nifedipine and lipophilic beta-adrenoceptor blockers.
摘要
在八名健康志愿者中研究了硝苯地平长期治疗对每日两次服用80毫克普萘洛尔、每日两次服用100毫克美托洛尔以及每日一次服用100毫克阿替洛尔药代动力学的影响。每日三次服用10毫克硝苯地平对美托洛尔和阿替洛尔的药代动力学没有影响，而硝苯地平使普萘洛尔的血浆峰浓度时间缩短了约1小时。普萘洛尔、美托洛尔和阿替洛尔在静息和运动时测得的心率下降程度相当。普萘洛尔、美托洛尔和阿替洛尔的β-肾上腺素能受体阻断特性不受与硝苯地平联合治疗的影响。本研究未显示硝苯地平和脂溶性β-肾上腺素能受体阻滞剂之间存在显著的药代动力学和药效学相互作用。
相似文献
1
Study of the influence of nifedipine on the pharmacokinetics and pharmacodynamics of propranolol, metoprolol and atenolol.硝苯地平对普萘洛尔、美托洛尔和阿替洛尔药代动力学及药效学影响的研究。
Br J Clin Pharmacol. 1984;17 Suppl 1(Suppl 1):29S-35S. doi: 10.1111/j.1365-2125.1984.tb02425.x.
2
Pharmacokinetics and pharmacodynamics of verapamil in combination with atenolol, metoprolol and propranolol.维拉帕米与阿替洛尔、美托洛尔和普萘洛尔联合应用的药代动力学和药效学。
Br J Clin Pharmacol. 1984;17 Suppl 1(Suppl 1):37S-44S. doi: 10.1111/j.1365-2125.1984.tb02426.x.
3
Interaction of metoprolol, propranolol and atenolol with concurrent administration of cimetidine.美托洛尔、普萘洛尔和阿替洛尔与西咪替丁同时给药时的相互作用。
Klin Wochenschr. 1982 Nov 15;60(22):1401-7. doi: 10.1007/BF01716245.
4
The interaction between H2-receptor antagonists and beta-adrenoceptor blockers.H2受体拮抗剂与β-肾上腺素能受体阻滞剂之间的相互作用。
Br J Clin Pharmacol. 1984;17 Suppl 1(Suppl 1):51S-57S. doi: 10.1111/j.1365-2125.1984.tb02428.x.
5
Lack of a pharmacokinetic interaction between nifedipine and the beta-adrenoceptor blockers metoprolol and atenolol.硝苯地平与β-肾上腺素受体阻滞剂美托洛尔和阿替洛尔之间不存在药代动力学相互作用。
Br J Clin Pharmacol. 1984 Sep;18(3):331-5. doi: 10.1111/j.1365-2125.1984.tb02472.x.
6
Diazepam/beta-adrenoceptor antagonist interactions.地西泮/β-肾上腺素能受体拮抗剂相互作用
Br J Clin Pharmacol. 1984;17 Suppl 1(Suppl 1):69S-76S. doi: 10.1111/j.1365-2125.1984.tb02431.x.
7
Single-dose kinetics of oral propranolol, metoprolol, atenolol, and sotalol: relation to lipophilicity.口服普萘洛尔、美托洛尔、阿替洛尔和索他洛尔的单剂量动力学：与亲脂性的关系。
Arzneimittelforschung. 1985;35(10):1580-2.
8
The effect of beta-adrenoceptor antagonists on the pharmacokinetics and pharmacodynamics of warfarin after a single dose.单次给药后β-肾上腺素能受体拮抗剂对华法林药代动力学和药效学的影响。
Br J Clin Pharmacol. 1984 May;17(5):553-7. doi: 10.1111/j.1365-2125.1984.tb02389.x.
9
Beta-adrenoceptor blockade and CNS-related subjective symptoms: a randomized, double-blind, placebo-controlled comparison of metoprolol CR/ZOK, atenolol and propranolol LA in healthy subjects.β-肾上腺素能受体阻滞剂与中枢神经系统相关主观症状：美托洛尔缓释片/佐剂、阿替洛尔和普萘洛尔长效制剂在健康受试者中的随机、双盲、安慰剂对照比较
J Clin Pharmacol. 1990 Feb;30(S2):S103-7. doi: 10.1002/j.1552-4604.1990.tb03506.x.
10
A comparison of the pharmacokinetics of atenolol, metoprolol, oxprenolol and propranolol in elderly hypertensive and young healthy subjects.阿替洛尔、美托洛尔、氧烯洛尔和普萘洛尔在老年高血压患者和年轻健康受试者体内的药代动力学比较。
Br J Clin Pharmacol. 1985 Oct;20(4):327-31. doi: 10.1111/j.1365-2125.1985.tb05072.x.
引用本文的文献
1
Clinical Pharmacokinetics of Metoprolol: A Systematic Review.美托洛尔的临床药代动力学：系统评价。
Clin Pharmacokinet. 2022 Aug;61(8):1095-1114. doi: 10.1007/s40262-022-01145-y. Epub 2022 Jun 28.
2
beta-blockers. Drug interactions of clinical significance.β受体阻滞剂。具有临床意义的药物相互作用。
Drug Saf. 1995 Dec;13(6):359-70. doi: 10.2165/00002018-199513060-00005.
3
Influences of the calcium antagonists nicardipine and nifedipine, and the calcium agonist BAY-K-8644, on the pharmacokinetics of propranolol in rats.钙拮抗剂尼卡地平与硝苯地平以及钙激动剂BAY-K-8644对大鼠体内普萘洛尔药代动力学的影响。
Cardiovasc Drugs Ther. 1993 Aug;7(4):721-6. doi: 10.1007/BF00877826.
4
Nifedipine. Relationship between pharmacokinetics and pharmacodynamics.硝苯地平。药代动力学与药效学之间的关系。
Clin Pharmacokinet. 1987 Jan;12(1):12-29. doi: 10.2165/00003088-198712010-00002.
5
Metoprolol. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in hypertension, ischaemic heart disease and related cardiovascular disorders.美托洛尔。对其药效学和药代动力学特性以及在高血压、缺血性心脏病和相关心血管疾病中的治疗效果的最新综述。
Drugs. 1986 May;31(5):376-429. doi: 10.2165/00003495-198631050-00002.
6
Effect of diltiazem on the pharmacokinetics of propranolol, metoprolol and atenolol.地尔硫䓬对普萘洛尔、美托洛尔和阿替洛尔药代动力学的影响。
Eur J Clin Pharmacol. 1989;36(1):67-70. doi: 10.1007/BF00561026.
7
Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders.硝苯地平。对其在缺血性心脏病、高血压及相关心血管疾病中的药效学、药代动力学特性及治疗效果的综述。
Drugs. 1985 Sep;30(3):182-274. doi: 10.2165/00003495-198530030-00002.
8
Influence of nicardipine on the pharmacokinetics and pharmacodynamics of propranolol in healthy volunteers.尼卡地平对健康志愿者中普萘洛尔药代动力学和药效学的影响。
Br J Clin Pharmacol. 1990 May;29(5):497-501. doi: 10.1111/j.1365-2125.1990.tb03671.x.
9
Nicardipine does not influence the pharmacokinetics and pharmacodynamics of atenolol.尼卡地平不影响阿替洛尔的药代动力学和药效学。
Br J Clin Pharmacol. 1990 Sep;30(3):499-500. doi: 10.1111/j.1365-2125.1990.tb03806.x.
10
Drug interactions in hypertensive patients. Pharmacokinetic, pharmacodynamic and genetic considerations.高血压患者的药物相互作用。药代动力学、药效学及遗传学考量
Clin Pharmacokinet. 1990 Apr;18(4):295-317. doi: 10.2165/00003088-199018040-00003.
本文引用的文献
1
Reduction of liver blood flow and propranolol metabolism by cimetidine.西咪替丁对肝血流量及普萘洛尔代谢的影响
N Engl J Med. 1981 Mar 19;304(12):692-5. doi: 10.1056/NEJM198103193041202.
2
Reduction in lidocaine clearance during continuous infusion and by coadministration of propranolol.连续输注利多卡因以及与普萘洛尔合用时，利多卡因清除率降低。
N Engl J Med. 1980 Aug 14;303(7):373-7. doi: 10.1056/NEJM198008143030705.
3
Interaction between oral propranolol and hydralazine.口服普萘洛尔与肼屈嗪之间的相互作用。
Clin Pharmacol Ther. 1980 Jun;27(6):726-32. doi: 10.1038/clpt.1980.103.
4
Cimetidine increases steady state plasma levels of propranolol.西咪替丁可提高普萘洛尔的稳态血药浓度。
Br J Clin Pharmacol. 1981 Dec;12(6):785-90. doi: 10.1111/j.1365-2125.1981.tb01307.x.
5
Lidocaine-propranolol interactions.利多卡因-普萘洛尔相互作用
N Engl J Med. 1981 May 21;304(21):1301. doi: 10.1056/nejm198105213042117.
6
Interaction of metoprolol, propranolol and atenolol with concurrent administration of cimetidine.美托洛尔、普萘洛尔和阿替洛尔与西咪替丁同时给药时的相互作用。
Klin Wochenschr. 1982 Nov 15;60(22):1401-7. doi: 10.1007/BF01716245.
7
Lack of effect of atenolol on antipyrine clearance.阿替洛尔对安替比林清除率无影响。
Br J Clin Pharmacol. 1982 Nov;14(5):743-4. doi: 10.1111/j.1365-2125.1982.tb04967.x.
8
The short term effects of propranolol, atenolol and labetalol on antipyrine kinetics in normal subjects.普萘洛尔、阿替洛尔和拉贝洛尔对正常受试者安替比林动力学的短期影响。
Br J Clin Pharmacol. 1982 Jun;13(6):817-20. doi: 10.1111/j.1365-2125.1982.tb01872.x.
9
Calcium channel blocking agents in the treatment of cardiovascular disorders. Part II: Hemodynamic effects and clinical applications.钙通道阻滞剂在心血管疾病治疗中的应用。第二部分：血流动力学效应及临床应用。
Ann Intern Med. 1980 Dec;93(6):886-904. doi: 10.7326/0003-4819-93-6-886.
10
Lidocaine elimination: effects of metoprolol and of propranolol.利多卡因的消除：美托洛尔和普萘洛尔的影响。
Clin Pharmacol Ther. 1983 Feb;33(2):133-8. doi: 10.1038/clpt.1983.20.
Zotero 插件